AngioDynamics Announces Availability of AngioFlow Thermal Dilution Catheter and AngioFlow Meter in the U.S.Business Editors/Health/Medical Writers QUEENSBURY, N.Y.--(BUSINESS WIRE)--April 20, 2004 AngioDynamics, Inc., a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of E-Z-EM, Inc., (AMEX AMEX See: American Stock Exchange :EZM) today announced the introduction of the AngioFlow(TM) Thermal Dilution Catheter and AngioFlow(TM) Meter in the United States, collectively known as the AngioFlow System. The AngioFlow System is a catheter-based flow meter the Company believes will be the first device to measure blood flow in hemodialysis access sites during an access site clearing procedure. Maintaining the patency of a vascular access graft or fistula fistula (fĭs`ch  lə), abnormal, usually ulcerous channellike formation between two internal organs or between an internal organ and the skin. is critical to the survival of patients with chronic renal failure chronic renal failure Chronic kidney failure Nephrology A slow decline in renal function, which may be 2º to chronic HTN, DM, CHF, SLE, or sickle cell anemia and, if extreme, leads to ESRD, mandating kidney dialysis; an abrupt decline in renal function may be . Several studies have determined that a blood flow less than 600ml/min is predictive of a developing stenosis within a graft or fistula. If left untreated, the graft or fistula will occlude (programming) occlude - (Or "shadow") To make a variable inaccessible by declaring another with the same name within the scope of the first. , and the patient will be unable to undergo hemodialysis treatment. Multiple endovascular and surgical interventions are frequently required to maintain patency of a vascular access. The AngioFlow System provides accurate and immediate blood flow measurements during these interventions. Dr. Tom Vesely, an Associate Professor of Radiology, Surgery, and Medicine at the Washington University School of Medicine Washington University School of Medicine, located in St. Louis, Missouri, is one of the most competitive and highly regarded medical schools and biomedical research institutes in the United States. in Saint Louis, has extensive clinical experience with the AngioFlow system. Commenting on this technology, Dr. Vesely stated, "The AngioFlow system provides valuable and immediate information that is useful for the detection of inconspicuous lesions, optimizing our reparative re·par·a·tive also re·par·a·to·ry adj. 1. Tending to repair. 2. Relating to or of the nature of reparations. procedures, and helping to restore full function to the patient's vascular access." Commenting for AngioDynamics, Don Geer, Director of Marketing for Vascular Access Products, said, "Due to the aging of the population and other factors, the long-term care of patients with chronic renal failure is a growing medical problem. The AngioFlow System helps physicians treat these patients by providing important data on blood flow through the vascular access graft site, and as such represents an important addition to AngioDynamics' dialysis product line. We are pleased to able to bring this important product to physicians and their patients." For additional information on the AngioFlow catheter and AngioFlow meter, contact Don Geer at 1-800-772-6446, ext. 167, Email: dgeer@angiodynamics.com or visit the AngioDynamics web site at www.angiodynamics.com. About AngioDynamics AngioDynamics, Inc. (www.angiodynamics.com) is a leading provider of innovative medical devices used in minimally invasive, image-guided procedures to treat peripheral vascular disease Peripheral Vascular Disease Definition Peripheral vascular disease is a narrowing of blood vessels that restricts blood flow. It mostly occurs in the legs, but is sometimes seen in the arms. . AngioDynamics designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat PVD PVD abbr. peripheral vascular disease PVD Peripheral vascular disease, see there and other non-coronary diseases. About E-Z-EM E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal radiology. The Company has developed the only CT injector on the market that can help detect contrast extravasation extravasation /ex·trav·a·sa·tion/ (ek-strav?ah-za´shun) 1. a discharge or escape, as of blood, from a vessel into the tissues; blood or other substance so discharged. 2. the process of being extravasated. , the EmpowerCT(R) with patented EDA(TM) technology; it also offers a complete product set for the virtual colonoscopy practitioner. This product line consists of virtual colonoscopy hardware, software, nutritional prep kits and bowel cleaners, tagging agents and a carbon dioxide colon insufflation insufflation /in·suf·fla·tion/ (-sah-fla´shun) 1. the act of blowing a powder, vapor, or gas into a body cavity. 2. finely powdered or liquid drugs carried into the respiratory passages by such devices as aerosols. system. The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, market acceptance of AngioFlow Thermal Dilution Catheter and AngioFlow Meter, future actions by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations, competition, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter ended February 28, 2004, as well as its Annual Report on Form 10-K for the year ended May 31, 2003, may affect the actual results achieved by the Company. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion